Biotech startup emerges from stealth with $65M to tackle lung cancer


Ribon Therapeutics hopes its lead program can restrain an enzyme that is activated by environmental stresses like cigarette smoking and allows cancerous cells to dodge the body's immune system.

Previous 16 states appealing Affordable Care Act ruling in Texas
Next Eye-tracking startup that helps diagnose concussions gets FDA's OK